Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2021

Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy

Clarice Groeneveld
Jacqueline Fontugne
  • Fonction : Auteur
Luc Cabel
  • Fonction : Auteur
Yves Allory
Aurélien de Reyniès
  • Fonction : Auteur

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-03453779 , version 1 (28-11-2021)

Identifiants

Citer

Clarice Groeneveld, Jacqueline Fontugne, Luc Cabel, Isabelle Bernard-Pierrot, François Radvanyi, et al.. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. European Journal of Cancer, 2021, 148, pp.181-189. ⟨10.1016/j.ejca.2021.01.036⟩. ⟨hal-03453779⟩
21 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More